Sorafenib-loaded Hydroxyethyl Starch-TG100-115 Micelles for the Treatment of Liver Cancer Based on Synergistic Treatment

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2019 Jul 31

PMID 31357893

Citations 12

Authors

Guofei Li

Limei Zhao

Affiliations

Soon will be listed here.

Abstract

Tumor microenvironment is closely related to the occurrence and development of liver cancer. Tumor-associated macrophages (TAMs) are an important part of tumor microenvironment promoting tumor deterioration and metastasis by inhibiting immune cells. Previous studies showed that PI3Kγ inhibitor could reverse the phenotype of TAMs, relieve immunosuppression and sensitize chemotherapy drugs, suggesting that the combination of PI3Kγ inhibitor and chemotherapeutics is likely to bring new breakthroughs in the treatment of liver cancer. Based on it, this paper builds HES-TG100-115-CDM-PEG micelles with tumor microenvironment responsiveness that simultaneously loaded sorafenib and TG100-115 to synergistically treat liver cancer. Pharmacokinetic study showed that the prepared micelles had longer half-life than that of the free drug solutions, which was favorable for high propensity of extravasation through tumor vascular fenestrations. Under low pH and high α-amylasereductive conditions, micelles could depolymerize quickly due to the sensitivity of bonds and enhance significantly cytotoxic activity against Hep-3B liver cancer cell. Additionally, micelles demonstrated higher levels of antitumor efficiency and better tolerance against nude mouse with Hep-3B cell than the free drug solutions. These findings reveal that HES-TG100-115-CDM-PEG micelles are a promising drug delivery system in clinical comprehensive therapy of liver cancer.

Citing Articles

Transforming Healthcare with Nanomedicine: A SWOT Analysis of Drug Delivery Innovation.

Zhang H, Li S, Ma X Drug Des Devel Ther. 2024; 18:3499-3521.

PMID: 39132625 PMC: 11314449. DOI: 10.2147/DDDT.S470210.

Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature.

Xu H, Russell S, Steiner K, ONeill E, Jones K Cancer Immunol Immunother. 2024; 73(10):204.

PMID: 39105848 PMC: 11303654. DOI: 10.1007/s00262-024-03779-2.

Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.

Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S Exp Hematol Oncol. 2024; 13(1):72.

PMID: 39085965 PMC: 11292955. DOI: 10.1186/s40164-024-00539-x.

PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer.

Curcio C, Mucciolo G, Roux C, Brugiapaglia S, Scagliotti A, Guadagnin G J Exp Clin Cancer Res. 2024; 43(1):157.

PMID: 38824552 PMC: 11143614. DOI: 10.1186/s13046-024-03080-1.

Advances in Polymeric Micelles: Responsive and Targeting Approaches for Cancer Immunotherapy in the Tumor Microenvironment.

Cheng L, Yu J, Hao T, Wang W, Wei M, Li G Pharmaceutics. 2023; 15(11).

PMID: 38004600 PMC: 10675796. DOI: 10.3390/pharmaceutics15112622.

References

Liu C, Chen K, Chen P . Treatment of Liver Cancer. Cold Spring Harb Perspect Med. 2015; 5(9):a021535. PMC: 4561392. DOI: 10.1101/cshperspect.a021535. View

Sun Y . Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2015; 380(1):205-15. DOI: 10.1016/j.canlet.2015.07.044. View

Setti A, Vijay Kumar M, Babu K, Rasagna A, Prasanna M, Devi T . Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers. J Recept Signal Transduct Res. 2016; 36(1):26-36. DOI: 10.3109/10799893.2014.1003658. View

Li G, Zhao M, Zhao L . Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment. Drug Deliv. 2016; 23(8):2860-2868. DOI: 10.3109/10717544.2015.1110844. View

Wu T, Dai Y . Tumor microenvironment and therapeutic response. Cancer Lett. 2016; 387:61-68. DOI: 10.1016/j.canlet.2016.01.043. View

Kaneda M, Cappello P, Nguyen A, Ralainirina N, Hardamon C, Foubert P . Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discov. 2016; 6(8):870-85. PMC: 5091937. DOI: 10.1158/2159-8290.CD-15-1346. View

Hu H, Li Y, Zhou Q, Ao Y, Yu C, Wan Y . Redox-Sensitive Hydroxyethyl Starch-Doxorubicin Conjugate for Tumor Targeted Drug Delivery. ACS Appl Mater Interfaces. 2016; 8(45):30833-30844. DOI: 10.1021/acsami.6b11932. View

Zhao K, Li D, Xu W, Ding J, Jiang W, Li M . Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer. Biomaterials. 2016; 116:82-94. DOI: 10.1016/j.biomaterials.2016.11.030. View

Birgani M, Carloni V . Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. Int J Mol Sci. 2017; 18(2). PMC: 5343939. DOI: 10.3390/ijms18020405. View

10.

Shi B, Huang K, Ding J, Xu W, Yang Y, Liu H . Intracellularly Swollen Polypeptide Nanogel Assists Hepatoma Chemotherapy. Theranostics. 2017; 7(3):703-716. PMC: 5327644. DOI: 10.7150/thno.16794. View

11.

Yang H, Woo H, Lee S, Han J, Jang B, Nam H . A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017; 23(2):128-137. PMC: 5497665. DOI: 10.3350/cmh.2016.0071. View

12.

Wei X, Pu J, Guo Z, Li T, Zhu D, Wu Z . [Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017; 33(5):617-622. View

13.

Feng Q, Tong R . Anticancer nanoparticulate polymer-drug conjugate. Bioeng Transl Med. 2018; 1(3):277-296. PMC: 5689533. DOI: 10.1002/btm2.10033. View

14.

Hanafy N, Dini L, Citti C, Cannazza G, Leporatti S . Inihibition of Glycolysis by Using a Micro/Nano-Lipid Bromopyruvic Chitosan Carrier as a Promising Tool to Improve Treatment of Hepatocellular Carcinoma. Nanomaterials (Basel). 2018; 8(1). PMC: 5791121. DOI: 10.3390/nano8010034. View

15.

Hsu C, Lin P, Tsai Y, Tsai M, Tseng C, Lin S . NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin. Cell Death Discov. 2018; 4:57. PMC: 5945618. DOI: 10.1038/s41420-018-0060-7. View

16.

Li J, Xu W, Li D, Liu T, Zhang Y, Ding J . Locally Deployable Nanofiber Patch for Sequential Drug Delivery in Treatment of Primary and Advanced Orthotopic Hepatomas. ACS Nano. 2018; 12(7):6685-6699. DOI: 10.1021/acsnano.8b01729. View

17.

Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T . Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. Cancer Res. 2018; 78(16):4586-4598. DOI: 10.1158/0008-5472.CAN-17-3841. View

18.

Zhang Y, Zhang J, Xu W, Xiao G, Ding J, Chen X . Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma. Acta Biomater. 2018; 77:63-73. DOI: 10.1016/j.actbio.2018.07.021. View

19.

Abdelmoneem M, Mahmoud M, Zaky A, Helmy M, Sallam M, Fang J . Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. J Control Release. 2018; 287:78-93. DOI: 10.1016/j.jconrel.2018.08.026. View

20.

Amano M, Castoldi A, Andrade-Oliveira V, Latancia M, Terra F, Correa-Costa M . The lack of PI3Kγ favors M1 macrophage polarization and does not prevent kidney diseases progression. Int Immunopharmacol. 2018; 64:151-161. DOI: 10.1016/j.intimp.2018.08.020. View